The global CAR T cell market is growing continuously due to innovation and development in this therapy. It is estimated, the Global CAR T cell therapy market size will exhibit a remarkable CAGR of 52% from 2019 to 2025.
According to the National Cancer Institute, Chimeric Antigen Receptor (CAR) T cell therapy is one type of treatment for cancer, which helps to change patients' T cells so they will attack cancer cells. Firstly the CAR T cell ingrown in the laboratory, and it was given to patients by infusion. CAR T cells' distinctive characteristic is to bind to an antigen on the cancer cells and kill them. CAR T cell therapy treatment is mostly used in blood cancer and some, among others. Recently, CAR T cell therapy has preferred over radiation and chemotherapy.
CAR T cells become activated when targeted over antigen and bind to it to destroy the specific cells. The transfer of T cells is an anti-cancer therapeutic process that focuses virtually on any tumor-associated antigen. These are only applicable for the blood cancers in earlier days, but later ion with the advanced technologies; these are moved to various types of cancers.
MARKET DRIVERS
Awareness regarding health and wellness, modification in various disorders, and government support across the world are vital factors that ramp up the CAR T cell therapy market. Although the t- cell treatment systems are available, all oncology specialty hospitals provide immediate therapy to patients in clinics and ambulatory centers, which help reach the highest CAR T cell market in the world. T cell therapy has the fastest growth rate in lymphoma treatment because it has not preferred another medication.
Additionally, the rise in chronic diseases like cancer across the world is crucial for the market to grow extensively. The government's increased support in introducing reimbursement schemes in favor of the poor people is also escalating the demand of the market. The rapid development in industries and aid across all regions is the new opportunity for the CAR T cell therapy market.
Furthermore, the implementation of procedures with advanced technologies and the introduction of innovative treatment procedures with fewer side effects are expected to surge the market's growth rate. Rise in investments in research institutes related to cell therapy is another considerable factor supporting market growth.
MARKET RESTRAINTS
Lack of awareness in the rural areas towards the therapeutic process for cancer disease is slightly restraining the CAR T cell therapy market's demand. The cost of this therapy is a bit expensive, which cannot be affordable by ordinary people is also hindering the demand of the market. An increasing adverse drug reaction concern with cell therapy in Cytokine syndrome problems and the neurological problem is expected to hamper the CAR T cell therapy market growth.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Target Antigen, Application, Product, Therapies and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
This research report on the global CAR T Cell therapy market segmented and sub-segmented based on target antigen, Application, Product, therapies, and Region.
CAR T cell Therapy Market - By Target Antigen
Based on target antigen, segments like CD/19 & CD/22 had the largest share in the global market in 2019 and is expected to continue their dominance throughout the forecast period. In recently, several companies got their antigens approved. It also increases the T cell therapy market. B-cell maturation antigens are anticipated to fastest growth due to its distinctive antigens such as MUC16, ROR1, and L1CAM.
CAR T cell Therapy Market - By Application
Based on Application, the Multiple Myeloma sector is leading with the highest shares of the market from the past decade and also estimated to continue the same growth in the coming years. Multiple myeloma segment has grown in T cell therapy market. The new acute lymphocytic leukemia segment is expected to grow in the coming decades. The Diffuse large B-cell lymphoma (DLBCL) segment is another lucrative segment and is standing next to occupying the second-best majority shares in the market.
CAR T cell Therapy Market - By Product
Based on the product, the autologous segment is anticipated to lead the CAR T Cell therapy market, which owes to several potential competitors, high costs associated with the market, and a considerable number of key players in the forthcoming years.
CAR T cell Therapy Market Analysis - By Therapies
Based on the therapies, the Tisagenlecleucel (Kymriah) segment is expected to account for the largest share in the CAR T cell therapy market. It is due to the increasing occurrence rate of lymphoblastic leukemia and early accessibility of products that assist in segment growth over the analysis period.
Axicabtagene ciloleucel (Yescarta) is expected to have considerable growth in the market over the analysis period due to developing healthcare infrastructure and growing discretionary expenses.
CAR T cell Therapy Market – By End User
Based on the end-user analysis, the biotechnology and pharmaceutical companies’ segment is witnessed to have a significant share in the market over the review period. Due to advanced research carried out at the companies, the segment is leading with the highest shares.
CAR T cell Therapy Market Analysis – By Region
Regionally, North America leads the global market. Because of the quick adoption of advanced technologies and the rise in cancer, patients are fueling the demand of the market in this region. North America region is continuously growing in the CAR T cell market by owing to academic institutions, government authority, and several manufacturing industries. Also, the United States is the highest market in the adoption of CAR T cell therapy. Also, some industries got USFDA Approval for the development of CAR T cell therapy treatment.
Followed by North America, Asia Pacific holds the highest shares of the market with the increased research process on the blood cancer treatment process. Asia-pacific is the growing market due to China and India; it has several manufacturing industries and the number of cancer patients from that Region.
Europe is the fastest-growing region in the CAR T cell market due to the recent approvals of Kymriah and Yescarta by European medicine agency; it will grow in the CAR T cell market.
TOP COMPANIES IN THE MARKET
Companies playing a leading role in the global CAR T cell therapy market profiled in this report are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc. and Pfizer, Inc.
RECENT MARKET DEVELOPMENTS
In Dec 2019, the Swiss government approved the insurance for CAR T cell therapies from Gilead Sciences and Novartis. The Novartis includes Kymriah and Gilead Yescarta therapies system for cancer treatment. The contract between hospitals and health insurers will approve in 2020.
In May 2020, Wuxi Advanced Therapies is a development and manufacturing industry which provides end to end the contract for innovative therapies. It wants to expand its facility into CAR-T Cell therapy to help gene therapy development and production units.
The new product UCART19 is processed in development for the treatment of CD/19 type of disease. Pfizer has partnered with allogeneic to enhance growth and business in allogeneic CAR T cell therapies.
In 2018, the Ziopharm Company partnered with Intrexon to advancement and development in CAR T cell cancer therapy treatment for substantial tumor disease.
